Advocacy Pays Off for ASCs
At the Outpatient Ophthalmic Surgery Society’s “OOSS Perspective 2026” symposium in Washington, DC, the organization's Washington counsel, Michael Romansky, JD, delivered an update on reimbursement, regulatory developments, and advocacy priorities affecting ophthalmic ambulatory surgery centers (ASCs).
By
Jennifer Ford, content director
Jennifer Ford, content director
May 1, 2026
Clinical Scorecard: Advocacy Pays Off for ASCs
At a Glance
Category Detail
Condition Ophthalmic Ambulatory Surgery Centers (ASCs)
Key Mechanisms Advocacy for reimbursement and regulatory changes impacting ASCs.
Target Population Patients undergoing ophthalmic surgeries, particularly cataract and retina procedures.
Care Setting Outpatient surgical centers.
Key Highlights
CMS proposed a 4.7% reduction in ASC payments for 2026, which was changed to a 3.4% increase after advocacy. Advocacy efforts resulted in approximately $150 million for ASCs performing cataract surgery. CMS will determine the update factor for ASCs in 2027, with recommendations to retain the Hospital Market Basket. Concerns raised about narrow definitions for non-opioid drug payments and compliance issues with prior authorization. Legislative efforts include the Outpatient Surgery Access Act of 2026 to address reimbursement concerns.
Guideline-Based Recommendations
Diagnosis
Monitor compliance with CMS prior authorization requirements.
Management
Advocate for broader definitions of eligible non-opioid drugs for separate payment.
Monitoring & Follow-up
Stay vigilant regarding payment restrictions for MIGS combination procedures.
Risks
Potential penalties for noncompliance with patient satisfaction survey vendor contracts.
Patient & Prescribing Data
Patients undergoing cataract and retinal surgeries.
Increased reimbursement for retina cases is being sought due to rising demand.
Clinical Best Practices
Engage in grassroots lobbying to influence policy changes. Utilize OOSS advocacy tools to contact legislators.
References